June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Paolo Tarantino: Dato-DXd is the Latest ADC to be Approved for Treating HR+/HER2- MBC
Jun 5, 2025, 08:58

Paolo Tarantino: Dato-DXd is the Latest ADC to be Approved for Treating HR+/HER2- MBC

Paolo Tarantino, 2025 Yvonne ‘Top Voice’ Award Winner, Research Fellow at Dana-Farber Cancer Institute, shared a post on LinkedIn:

“Dato-DXd is the latest ADC to be approved for treating HR+/HER2- MBC, joining two other topo1 ADCs (T-DXd, SG).
How should we sequence these agents?
We conducted multiple rounds of polling to generate consensus within the Dana-Farber Cancer Institute Breast Oncology group.
The resulting consensus document is now published.”

Read More.

Dato-DXd

More posts featuring Paolo Tarantino on OncoDaily.